Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Liraglutide and its Neuroprotective Properties—Focus on Possible Biochemical Mechanisms in Alzheimer’s Disease and Cerebral Ischemic Events
Michał Wiciński, Maciej W. Socha, Bartosz Malinowski, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1050-1050
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 251
Drug repositioning: Progress and challenges in drug discovery for various diseases
Yi Hua, Xiaowen Dai, Yuan Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 234, pp. 114239-114239
Open Access | Times Cited: 123
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 114
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Christian Hölscher
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 4, pp. 333-348
Open Access | Times Cited: 135
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Christian Hölscher
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 695-714
Open Access | Times Cited: 95
Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury
Michał Wiciński, Eryk Wódkiewicz, Karol Górski, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 11, pp. 379-379
Open Access | Times Cited: 82
Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis‐related NLRP3 pathway
Shuang Song, Ruoyi Guo, Arshad Mehmood, et al.
CNS Neuroscience & Therapeutics (2022) Vol. 28, Iss. 3, pp. 422-434
Open Access | Times Cited: 66
High frequency repetitive transcranial magnetic stimulation alleviates cognitive deficits in 3xTg-AD mice by modulating the PI3K/Akt/GLT-1 axis
Huấn Cao, Chengchao Zuo, Zhongya Gu, et al.
Redox Biology (2022) Vol. 54, pp. 102354-102354
Open Access | Times Cited: 47
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Muna A. Adem, Boris Decourt, Marwan N. Sabbagh
Biomedicines (2024) Vol. 12, Iss. 1, pp. 99-99
Open Access | Times Cited: 15
Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications
Mateusz Kciuk, Weronika Kruczkowska, Julia Gałęziewska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11955-11955
Open Access | Times Cited: 11
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Binbin Gong, Zhihong Yao, Chenxu Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116342-116342
Closed Access | Times Cited: 8
Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation
Ana I. Duarte, Emanuel Candeias, Inês N. Alves, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 5, pp. 1746-1746
Open Access | Times Cited: 68
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Xiaoyan Yang, Peng Feng, Rong Ji, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 445-460
Closed Access | Times Cited: 28
<p>Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease</p>
Shanshan Hu, Meigui Hu, Jian Liu, et al.
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 651-663
Open Access | Times Cited: 44
Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease
Jong Youl Kim, Sumit Barua, Ye Jun Jeong, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6419-6419
Open Access | Times Cited: 42
Copper, Iron, Selenium and Lipo-Glycemic Dysmetabolism in Alzheimer’s Disease
Jan Aaseth, Anatoly V. Skalny, Per M. Roos, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9461-9461
Open Access | Times Cited: 40
Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway
Mohamed A. Sadek, Esraa A. Kandil, Nesrine S. El Sayed, et al.
International Immunopharmacology (2022) Vol. 115, pp. 109647-109647
Closed Access | Times Cited: 25
Mitochondrial Complex I, a Possible Sensible Site of cAMP Pathway in Aging
Anna Signorile, Domenico De Rasmo
Antioxidants (2023) Vol. 12, Iss. 2, pp. 221-221
Open Access | Times Cited: 14
Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation
Yara S. Abdelkawy, Mona Elharoun, Eman Sheta, et al.
European Journal of Pharmacology (2024) Vol. 971, pp. 176525-176525
Closed Access | Times Cited: 5
A review on α-mangostin as a potential multi-target-directed ligand for Alzheimer's disease
Ai‐Hong Yang, Chang Liu, Jiarui Wu, et al.
European Journal of Pharmacology (2021) Vol. 897, pp. 173950-173950
Closed Access | Times Cited: 28
Role of liraglutide in Alzheimer’s disease pathology
María Vargas-Soria, María José Carranza-Naval, Ángel del Marco, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 27
γ-Glutamylcysteine Exerts Neuroprotection Effects against Cerebral Ischemia/Reperfusion Injury through Inhibiting Lipid Peroxidation and Ferroptosis
Ruyi Zhang, Jianzhen Lei, Luyao Chen, et al.
Antioxidants (2022) Vol. 11, Iss. 9, pp. 1653-1653
Open Access | Times Cited: 22
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
C. Duta, Corina Muscurel, Carmen Beatrice Dogaru, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1516-1516
Open Access
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
Xiaoke Dou, Lei Zhao, Jing Li, et al.
Frontiers in Neuroscience (2025) Vol. 19
Open Access
The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders
Junchen Si, Kai Yu, Jiheng Hao, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Page 1 - Next Page

Scroll to top